<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698473</url>
  </required_header>
  <id_info>
    <org_study_id>18-AKD-138</org_study_id>
    <nct_id>NCT04698473</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV</brief_title>
  <official_title>Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV in Premature Babies: CURLISPAP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uludag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non invasive ventilation is important in the care of preterm infants with respiratory&#xD;
      failure, and surfactant treatment can be use with non invasive ventilation. However, there is&#xD;
      no consensus on the best non-invasive ventilation mode for surfactant treatment in preterm&#xD;
      infants.&#xD;
&#xD;
      Objective: To compare the effectiveness of nasal intermittent positive pressure ventilation&#xD;
      (NIPPV) versus nasal continuous positive airway pressure (CPAP) in preterm infants ≤ 29 week&#xD;
      gestational age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This CURLISPAP study was a multicenter, randomized controlled study at six level III neonatal&#xD;
      intensive care units (NICUs) in Turkey. The protocol was approved by the ethics committee of&#xD;
      each participating centre and Turkish Ministry of Health, Turkish Medicines and Medical&#xD;
      Devices Agency.&#xD;
&#xD;
      Non invasive ventilated preterm infants with respiratory distress syndrome and gestational&#xD;
      age from 241/7 weeks to 296/7 weeks were enrolled within 6 h of birth. Infants with major&#xD;
      congenital malformations, need of mechanical ventiation, need of entubation in delivery room&#xD;
      and lack of parental consent were excluded. Enrolled infants will randomize into two study&#xD;
      groups (NIPPV group and CPAP group). The short binasal prongs will use as interface. For all&#xD;
      the groups, if the fraction of inspired oxygen (FiO2) requirement is persistently higher than&#xD;
      0.30 target SpO2 90-94%.&#xD;
&#xD;
      For all groups Surfactant by &quot;LISA&quot; technique and with special catheter (LISAcath, Chiesi&#xD;
      Pharmaceutics) of surfactant (Curosurf, Chiesi Pharmaceutics) 200 mg/kg.&#xD;
&#xD;
      The primary end-point, need of mechanical ventilation within 72 hours following surfactant&#xD;
      treatment, will compared between the groups. Short and long-term neonatal outcomes will also&#xD;
      evaluate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure within 72 hours after randomization 72 hours after randomization</measure>
    <time_frame>within 72 hours after randomization</time_frame>
    <description>Need for invasive mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks of postmenstrual age ]</time_frame>
    <description>defined according to the NICHD definition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>NCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94.&#xD;
Failure is defined as FiO2 requirement of &gt;%50, capillary blood gas obtained at the 4th hour of therapy showing pH&lt;7.20 or pCO2&gt;60 cmH2O.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIPPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94.&#xD;
Failure is defined as FiO2 requirement of &gt;%50, capillary blood gas obtained at the 4th hour of therapy showing pH&lt;7.20 or pCO2&gt;60 cmH2O.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NCPAP</intervention_name>
    <description>NCPAP infants will be randomized into two different non invasive ventilation groups</description>
    <arm_group_label>NCPAP</arm_group_label>
    <arm_group_label>NIPPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NIPPV</intervention_name>
    <description>NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups</description>
    <arm_group_label>NCPAP</arm_group_label>
    <arm_group_label>NIPPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age 24 -29 week&#xD;
&#xD;
          -  Clinical and radiological diagnosis of RDS&#xD;
&#xD;
          -  Born in a hospital with a study center&#xD;
&#xD;
          -  Spontaneous breathing&#xD;
&#xD;
          -  Within the first 6 hours&#xD;
&#xD;
          -  Non-invasive ventilation and FiO2 requirement &gt;0.30&#xD;
&#xD;
          -  Parental concent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major congenital malformations&#xD;
&#xD;
          -  Need of mechanical ventiation&#xD;
&#xD;
          -  Need of entubation in delivery room&#xD;
&#xD;
          -  Air weak syndrome&#xD;
&#xD;
          -  No parental concent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>29 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hilal ozkan</last_name>
    <role>Study Director</role>
    <affiliation>Study director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hilal ozkan, professor</last_name>
    <phone>+905327608083</phone>
    <email>hiozkan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hilal Ozkan</name>
      <address>
        <city>Bursa</city>
        <state>Select...</state>
        <zip>16285</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hilal ozkan</last_name>
      <phone>05327608083</phone>
      <email>hiozkan@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, Groneck P, Weller U, Möller J, Härtel C, Haller S, Roth B, Herting E; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011 Nov 5;378(9803):1627-34. doi: 10.1016/S0140-6736(11)60986-0. Epub 2011 Sep 29.</citation>
    <PMID>21963186</PMID>
  </reference>
  <results_reference>
    <citation>Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev. 2016 Dec 15;12:CD005384. doi: 10.1002/14651858.CD005384.pub2. Review.</citation>
    <PMID>27976361</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uludag University</investigator_affiliation>
    <investigator_full_name>Hilal Ozkan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>NCPAP</keyword>
  <keyword>NIPPV</keyword>
  <keyword>LISA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04698473/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

